Key Takeaways for Johnson & Johnson Stock as of September 2026
- CFO Joe Wolk told analysts Johnson & Johnson’s capital allocation priorities stay unchanged, with the dividend still the primary route for returning capital even as full-year free cash flow guidance climbs toward $21 billion.
- Johnson & Johnson stock’s payout ratio sits at 58.31%, down from 61.20% the quarter before, while the dividend itself climbed to $1.34 a share.
- The quarterly dividend has risen from $1.24 to $1.30 and now to $1.34 over the past two years, a run of increases the payout ratio has comfortably absorbed.
- TIKR’s mid case model puts a $291 target on Johnson & Johnson stock by 12/31/30, a 10% total return worth a 2% annualized rate from today’s $266.
Johnson & Johnson Reaffirms Its Dividend As Free Cash Flow Guidance Climbs
Johnson & Johnson (JNJ) used its second quarter 2026 call to reaffirm exactly how it plans to keep paying shareholders. CFO Joe Wolk told analysts capital allocation priorities remain unchanged: the company will keep prioritizing investment in its commercial launches and future innovation, and “acquisitions are an enabler of growth, but they are not a requirement to deliver on our near- and long-term objectives.” Wolk was direct about where the dividend fits into that plan. “We also remain committed to returning capital directly to shareholders, primarily through our dividend,” he said.
That commitment comes with real cash behind it. Wolk said free cash flow was light in the first quarter but improved significantly in the second, with year to date free cash flow totaling approximately $8.7 billion. He said the company remains on track for a full year free cash flow outlook approaching $21 billion. Johnson & Johnson also ended the quarter with roughly $21 billion in cash and marketable securities against about $49 billion in debt, for a net debt position of approximately $28 billion.
The quarter’s operating results back up that guidance. Worldwide sales reached $25.3 billion, up 6% operationally, and the company raised its full year operational sales growth outlook to a midpoint of $100.6 billion. Adjusted operational earnings per share guidance rose to $11.50 to $11.65, a $0.18 increase at the midpoint and 7% growth year over year. Wolk also flagged the pending Firefly Bio acquisition, expected to close in the third quarter, as an example of the kind of bolt-on deal the company pursues without disturbing its capital return priorities. None of that acquisition activity is included in the raised guidance.
Set against that backdrop, Johnson & Johnson stock’s dividend reads less like a standalone decision and more like one piece of a capital allocation plan the company says will not change, funded by cash flow it just raised its outlook for.
JNJ Stock’s Payout Ratio Cools While Its Yield Nears a Low
Johnson & Johnson’s quarterly dividend has moved in one direction across the past two years, from $1.24 to $1.30 and now to $1.34 as of the period ending June 28, 2026.
The payout ratio backing those increases swung wildly earlier in the stretch, from 110.80% down to 27.18%, before settling into a steadier band.
By the most recent reading it stood at 58.31%, down from 61.20% the quarter before and its lowest print since the 56.51% reading in the quarter ended June 29, 2025.
That combination, a dividend still rising and a payout ratio easing, arrives even as Johnson & Johnson stock’s yield has compressed to 2.01%, just above its two-year low of 1.92% and well under its 2.88% mean.
Income investors will note the 2.01% yield sits far below the 3.45% high of the past two years, while total-return investors will point to a dividend that just climbed to $1.34 regardless of where the yield sits.
TIKR’s Model Sees Johnson & Johnson Stock Reaching $291 by 2030
TIKR’s mid case valuation model puts a $291 target price on Johnson & Johnson stock, realized by 12/31/30, for a 10% total return and a 2% annualized rate from today’s $266.
That return places Johnson & Johnson stock closer to a steady compounder than a re-rating story, with price appreciation and dividend income both contributing rather than one carrying the whole case.
The target lines up with a company guiding sales toward a $100.6 billion midpoint and adjusted operational earnings per share as high as $11.65, funded by free cash flow the company expects to approach $21 billion this year. Johnson & Johnson stock’s path to $291 depends far more on that underlying growth and cash generation holding up than on any single capital return decision.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Johnson & Johnson stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
